Highlights
1 patentProfile claimed by owner
About
Drug for ALS
NeuroSense Therapeutics is a drug development company offering a treatment for patients with amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The companys drug, PrimeC, is a unique formulation combining two FDA-approved compounds for unrelated conditions. The company was granted an orphan drug designation by the FDA and the EMA for the use of PrimeC in ALS patients. NeuroSense Therapeutics is currently running two clinical trials in patients with ALS, in Israel and the United States.
Identity
| Name | NeuroSense Therapeutics |
|---|---|
| Slug | neurosense-therapeutics |
| Type / kind | startup |
| Crunchbase ID | neuroene-therapeutics |
| Source _id | agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAwJ2g-5UKDA |
Status
| Status | active |
|---|---|
| Status reason | Public on NASDAQ on Dec, 2021; |
| Last update | 2026-05-17 |
Location
| HQ country code | IL |
|---|---|
| HQ region/district | Center District |
| HQ city | Herzliya |
| HQ address | Ha-Menofim St 11, Herzliya, Israel |
Web & social
Classifications
Primary sector Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
Biologicals
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business models
B2B
Tags
pharmaceuticalsamyotrophic-lateral-sclerosis-alsdrug-discoverypharma-companiesneurosciencebiotechnologydegenerative-diseasesrare-diseases
Funding
| Total raised | $24.2M |
|---|---|
| Current stage | Public |
| Market cap | $22.8M |
Raw source document
Show full JSON (0 KB)
{
"0": "s",
"1": "l",
"2": "i",
"3": "m",
"4": "p",
"5": "a",
"6": "g",
"7": "e",
"8": "s",
"9": "_",
"10": "i",
"11": "m",
"12": "p",
"13": "o",
"14": "r",
"15": "t"
}